Meridian Investment Counsel’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$910K Hold
96,433
– – 0.21% 112
2026
Q2
$844K Hold
96,433
– – 0.18% 127
2026
Q1
$740K Hold
96,433
– – 0.18% 127
2025
Q4
$191K Hold
96,433
– – 0.05% 235
2025
Q3
$237K Hold
96,433
– – 0.06% 210
2025
Q2
$255K Hold
96,433
– – 0.07% 205
2025
Q1
$290K Hold
96,433
– – 0.09% 182
2024
Q4
$247K Hold
96,433
– – 0.07% 197
2024
Q3
$359K Hold
96,433
– – 0.11% 158
2024
Q2
$609K Hold
96,433
– – 0.19% 119
2024
Q1
$518K Hold
96,433
– – 0.17% 129
2023
Q4
$484K Hold
96,433
– – 0.17% 133
2023
Q3
$163K Hold
96,433
– – 0.06% 195
2023
Q2
$268K Hold
96,433
– – 0.1% 181
2023
Q1
$176K Hold
96,433
– – 0.07% 196
2022
Q4
$489K Hold
96,433
– – 0.2% 119
2022
Q3
$479K Hold
96,433
– – 0.21% 114
2022
Q2
$359K Hold
96,433
– – 0.15% 144
2022
Q1
$541K Hold
96,433
– – 0.19% 118
2021
Q4
$586K Hold
96,433
– – 0.19% 115
2021
Q3
$939K Hold
96,433
– – 0.34% 83
2021
Q2
$1.38M Hold
96,433
– – 0.49% 61
2021
Q1
$2.29M Hold
96,433
– – 0.88% 32
2020
Q4
$1.28M Hold
96,433
– – 0.54% 51
2020
Q3
$669K Hold
96,433
– – 0.32% 76
2020
Q2
$1.18M Buy
+96,433
New +$544K 0.6% 48

Other funds holding IBRX

Meridian Investment Counsel's IBRX Position: Q3 2026 in Review

Meridian Investment Counsel held its ImmunityBio (IBRX) position steady in Q3 2026 at 96,433 shares worth $910K. The position accounts for 0.21% of the portfolio, ranked #112.

Meridian Investment Counsel first reported a position in IBRX in Q2 2020 and has held it in 26 quarters since. The position peaked at $2.29M in Q1 2021. 46 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Meridian Investment Counsel held 96,433 shares of ImmunityBio worth $910K as of Q3 2026.
  • Meridian Investment Counsel left its ImmunityBio share count unchanged in Q3 2026.
  • ImmunityBio made up 0.21% of Meridian Investment Counsel's portfolio in Q3 2026, its #112 holding.
  • Meridian Investment Counsel first reported a position in ImmunityBio in Q2 2020 and has held it in 26 quarters since.
  • Meridian Investment Counsel's ImmunityBio position peaked at $2.29M in Q1 2021.
  • 46 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Meridian Investment Counsel's 13F filing for Q3 2026, filed 14 Oct 2026.